Clinical-stage biotechnology company TME Pharma N.V. (Euronext Growth Paris: ALTME) announced on Monday a strategic plan to externalise and monetise its second clinical-stage asset, NOX-E36, targeting ophthalmic diseases. NOX-E36, an L-stereoisomer RNA aptamer inhibiting the CCL2 chemokine, has shown promising anti-fibrotic effects in preclinical studies by the Singapore Eye Research Institute.
Plans involve creating a separate corporate entity focused on developing NOX-E36 for ophthalmology to attract private investment. Preclinical and clinical data support a rapid transition to Phase 2 clinical trials. NOX-E36 has demonstrated efficacy in preventing fibrosis in glaucoma surgery models and has shown a strong safety and tolerability profile in 175 clinical trial participants.
Fibrosis significantly impacts the treatment of several eye diseases, including diabetic retinopathy, age-related macular degeneration and primary open-angle glaucoma. NOX-E36's anti-fibrotic mode of action positions it as a potential solution for these conditions.
TME Pharma specializes in developing therapies targeting the tumour microenvironment (TME) and cancer immunity cycle. The company's lead candidate, NOX-A12, is being evaluated in Phase 1/2 trials for glioblastoma and other cancers, with promising results observed in combination with radiotherapy and bevacizumab.
NOX-E36's transition to a dedicated ophthalmology-focused entity will enable TME Pharma to leverage its potential in addressing unmet medical needs in eye diseases, furthering its strategy to focus on oncology treatments.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial